Market closed
Candel Therapeutics/$CADL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Ticker
$CADL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
38
Website
CADL Metrics
BasicAdvanced
$248M
-
-$1.74
-1.28
-
Price and volume
Market cap
$248M
Beta
-1.28
52-week high
$9.13
52-week low
$4.96
Financial strength
Current ratio
2.766
Quick ratio
2.735
Long term debt to equity
4.538
Total debt to equity
20.31
Interest coverage (TTM)
-15.61%
Management effectiveness
Return on assets (TTM)
-27.55%
Return on equity (TTM)
-139.56%
Valuation
Price to book
3.71
Price to tangible book (TTM)
3.71
Price to free cash flow (TTM)
-6.15
Growth
Earnings per share change (TTM)
32.86%
3-year earnings per share growth (CAGR)
-3.09%
CADL News
AllArticlesVideos
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409
Proactive Investors·4 days ago
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
GlobeNewsWire·4 days ago
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI
Proactive Investors·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Candel Therapeutics stock?
Candel Therapeutics (CADL) has a market cap of $248M as of April 05, 2025.
What is the P/E ratio for Candel Therapeutics stock?
The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of April 05, 2025.
Does Candel Therapeutics stock pay dividends?
No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Candel Therapeutics dividend payment date?
Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.
What is the beta indicator for Candel Therapeutics?
Candel Therapeutics (CADL) has a beta rating of -1.28. This means that it has an inverse relation to market volatility.